|Systematic (IUPAC) name|
|Licence data||US FDA:|
|CAS Registry Number|
|Molecular mass||456.46 g/mol|
|(what is this?)|
It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration approved azilsartan medoxomil for the treatment of high blood pressure in adults. On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. 
Azilsartan should not be used with aliskiren, a renin inhibitor, in patients with diabetes as this increases the risk of serious adverse effects.
Mechanism of action
Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.
- "FDA approves Edarbi to treat high blood pressure" (Press release). U.S. Food and Drug Administration. February 25, 2011. Retrieved 2011-03-01.
- Notice of Decision for EDARBI
|This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.|